Xiaflex

Drug Overview

In the specialized field of [Rheumatology] and orthopedic medicine, treating structural deformities often requires interventions that go beyond traditional immune suppression. Xiaflex is a highly unique and localized medication classified within the Enzyme (Proteolytic) drug class. For patients experiencing the debilitating, progressive finger curling of Dupuytren’s contracture or the physical distortion of Peyronie’s disease, finding an effective, non-surgical intervention is a critical clinical goal.

Unlike a systemic DMARD (Disease-Modifying Antirheumatic Drug) or a traditional oral Small Molecule pill that circulates throughout the entire body, Xiaflex acts as a highly localized, injectable Targeted Therapy. It is administered directly into the fibrotic tissue, working to physically dissolve the collagen bands that restrict movement and cause chronic pain, thereby restoring normal anatomy without the need for invasive open surgery.

• Generic Name: collagenase clostridium histolyticum
• US Brand Names: Xiaflex
• Route of Administration: Intralesional injection (administered directly into the palpable cord or plaque by a specially trained healthcare provider)
• FDA Approval Status: FDA-approved for the treatment of adult patients with Dupuytren’s contracture with a palpable cord, and for adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees.
  
  Looking for information on Xiaflex? Discover how this Enzyme (Proteolytic) helps manage peyronie’s and dupuytren’s contracture. Read expert insights and medical guidelines for better health outcomes.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Xiaflex provides relief, it is essential to look at the biology of connective tissue. In healthy hands, a layer of tissue under the skin called the fascia is flexible and allows the fingers to glide smoothly. In patients suffering from Dupuytren’s contracture, the body abnormally deposits thick, rigid ropes of collagen (types I and III collagen). These ropes, or “cords,” pull the fingers toward the palm and prevent them from straightening.

Xiaflex is a purified biological product consisting of two specific proteolytic enzymes (collagenase AUX-I and collagenase AUX-II) derived from the bacterium Clostridium histolyticum. Its mechanism of action operates directly at the molecular level:

1. Enzymatic Cleavage: When injected directly into the abnormal cord, the two collagenases work synergistically to target and hydrolyze (break apart) the peptide bonds within the triple-helix structure of the collagen.
2. Tissue Dissolution: By dissolving the structural integrity of the collagen matrix, the rigid cord becomes weakened and fragmented.
3. Mechanical Disruption: Following the enzymatic breakdown (usually 24 to 72 hours post-injection), the physician performs a physical manipulation of the finger. Because the cord has been chemically degraded, this manipulation “snaps” or ruptures the cord, immediately restoring joint extension and releasing the contracture. This avoids the systemic suppression associated with a typical Biologic used for autoimmune joint destruction.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved indication for Xiaflex in this category is the treatment of Dupuytren’s contracture in adults with a palpable cord. It is also primarily indicated for the urological treatment of Peyronie’s disease.

Other Approved & Off-Label Uses

While officially approved for Dupuytren’s and Peyronie’s, specialists occasionally explore proteolytic enzymes for other fibrotic connective tissue disorders:

• Adhesive Capsulitis (Frozen Shoulder) (Active clinical trials)
• Plantar Fibromatosis (Ledderhose Disease) (Off-label)
• Note: It is not used to treat systemic autoimmune diseases like Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis, as it does not modulate the immune system.
• Primary Rheumatology Indications:
  • Contracture Release: Acts as a localized Targeted Therapy to physically break down the collagen cords that cause severe finger joint flexion deformities.
  • Functional Improvement: Dramatically improves physical function by restoring the range of motion (ROM) in the metacarpophalangeal (MP) or proximal interphalangeal (PIP) joints.
  • Delaying or Avoiding Surgery: Provides a minimally invasive alternative to fasciectomy (open hand surgery).

Dosage and Administration Protocols

Xiaflex is administered directly into the fibrotic cord or plaque by a healthcare provider who has completed specific training in its use. The procedure involves the injection phase followed by a physical manipulation phase.

Dose Adjustments: Because Xiaflex is a highly localized treatment that does not enter systemic circulation in significant amounts, dose adjustments for hepatic (liver) or renal (kidney) impairment are not required.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical study data from 2020 to 2026 continues to validate the use of Xiaflex for durable contracture release. Because it is a localized enzyme rather than a systemic DMARD, its efficacy is not measured by traditional rheumatology metrics like ACR20/50/70 response rates or DAS28-ESR improvements. Instead, efficacy is measured by the degree of contracture reduction and improvements in the Range of Motion (ROM).

In extensive clinical trials, over 60% of patients treated with Xiaflex achieved clinical success, defined as a reduction in contracture to 5 degrees or less within 30 days of the last injection. Backup research data confirms that patients treated with this Targeted Therapy experience a significant increase in hand function, allowing them to perform daily activities like washing their face, putting on gloves, or typing. Long-term observational studies show that while recurrence of the cord can happen (as the underlying genetic predisposition to produce collagen remains), the medication is highly efficacious in halting the immediate structural disability caused by the disease.

Safety Profile and Side Effects

BLACK BOX WARNING: Xiaflex carries a Black Box Warning for corporal rupture (penile fracture) or other serious penile injuries when used for Peyronie’s disease. Because of these severe risks, it is only available for Peyronie’s disease through a restricted program called the XIAFLEX REMS Program. For Dupuytren’s contracture, it carries warnings for tendon rupture.

Common side effects (>10%)

• Injection Site Reactions: Significant swelling, bruising, bleeding, and localized pain at the injection site are extremely common and expected as the enzyme breaks down the tissue.
• Lymphadenopathy: Swollen lymph nodes under the arm on the treated side.
• Pruritus: Itching or skin tearing near the injection site during the finger extension procedure.

Serious adverse events

• Tendon or Ligament Damage: If the enzyme is accidentally injected into a healthy flexor tendon rather than the targeted cord, it can cause the tendon to rupture, requiring immediate corrective surgery.
• Nerve Injury: Localized nerve damage causing numbness or tingling.
• Anaphylaxis: Severe allergic reactions, as the medication is derived from a bacterial source.

Management Strategies: To prevent tendon rupture, physicians must isolate the cord perfectly before injecting. Following the finger extension procedure, patients must wear a specialized splint at night for up to four months to keep the finger straight while the tissue heals. No systemic “add-back” therapies for bone density are required.

Research Areas

Direct Clinical Connections: Current research actively explores the interaction between exogenous collagenase and local synovial fibroblasts. Studies focus on how this Targeted Therapy not only dissolves existing cords but may temporarily alter the local cellular environment to downregulate the overproduction of collagen. Researchers are also evaluating its role in localized cartilage preservation by ensuring that the severe joint contracture does not lead to secondary degenerative joint damage from immobility.

Generalization: Between 2020 and 2026, clinical trials have heavily focused on expanding the use of Xiaflex into other fibrotic disorders. A major area of active research is its use in Adhesive Capsulitis (frozen shoulder), aiming to dissolve the fibrotic joint capsule and restore shoulder mobility without surgery.

Severe Disease & Systemic Involvement: While Dupuytren’s is typically localized to the hands, research confirms that restoring hand mobility with Xiaflex helps prevent the cascading extra-articular manifestations of the disease, such as the profound loss of independence, depression, and inability to perform self-care that often accompanies severe hand deformities.

Disclaimer: The content provided is for informational use and does not constitute medical advice. Please consult with a qualified healthcare professional to discuss specific clinical applications, risks, or therapeutic alternatives. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Measurement of the contracture angle using a goniometer. Completion of hand function questionnaires and baseline pain scores.
• Organ Function: While Xiaflex does not affect the internal organs, Hepatic monitoring (LFTs) and Renal function tests are often maintained by the rheumatologist if the patient is on common DMARD co-therapy for a separate overlapping condition (like Rheumatoid Arthritis).
• Specialized Testing: Careful physical examination to distinguish a Dupuytren’s cord from a flexor tendon or underlying joint deformity.
• Screening: Review of bleeding disorders or the use of anticoagulants (blood thinners), as the injection and manipulation process causes significant local bruising and bleeding.

Monitoring and Precautions

• Vigilance: Close monitoring is required in the days following the injection. The patient must return to the clinic 24 to 72 hours post-injection for the physician to perform the physical finger extension procedure.
• Lifestyle: Following the finger extension, strict adherence to hand therapy is vital. Patients must perform daily finger flexion and extension exercises to maintain the newly acquired range of motion.
• Splinting: Use of a custom-fitted night splint for several months is critical to prevent the tissue from contracting as it heals.

“Do’s and Don’ts” list

• DO keep your hand elevated above your heart for the first 48 hours after the injection to reduce severe swelling.
• DO wear your prescribed night splint exactly as instructed by your hand therapist.
• DO perform your daily hand exercises to train the finger to stay straight.
• DON’T attempt to bend or straighten the finger yourself immediately after the injection; wait for the physician to perform the controlled extension procedure.
• DON’T perform heavy lifting or strenuous gripping activities with the treated hand until your doctor clears you.
• DON’T ignore sudden numbness, extreme pain, or an inability to move your finger, as these could be signs of a tendon rupture or nerve injury.

Legal Disclaimer

This medical guide is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Xiaflex is a highly specialized biological product that must be administered by a healthcare professional formally trained in its use. Always consult your rheumatologist, orthopedic hand surgeon, or primary care physician with any questions you may have regarding hand contractures or potential treatment plans. Never disregard professional medical advice or delay seeking it because of information provided in this guide.